{
  "drug_name": "Cefoperazone-sulbactam",
  "tradename": "Sulperazon, Magnex",
  "usage_and_dosing": {
    "general": [
      "Cefoperazone is a 3rd generation parenteral extended spectrum cephalosporin active vs cell wall and cell membrane.",
      "It is available in a fixed dose combination with Sulbactam (a Class A beta-lactamase inhibitor).",
      "Sulbactam-Cefoperazone is active against all organisms susceptible to Cefoperazone with up to a 4-fold reduction in MICs for the combination compared to the Cefoperazone component against selected enteric Gram-negative species.",
      "Used for a variety of respiratory, skin-soft tissue, urinary tract and intra-abdominal infections.",
      "Product availability:"
    ],
    "product_availability": [
        {"vial_size": "1 gm", "sulbactam": "0.5 gm", "cefoperazone": "0.5 gm", "ratio": "1:1"},
        {"vial_size": "1.5 gm", "sulbactam": "0.5 gm", "cefoperazone": "1 gm", "ratio": "1:2"},
        {"vial_size": "2 gm", "sulbactam": "1 gm", "cefoperazone": "1 gm", "ratio": "1:1"},
        {"vial_size": "3 gm", "sulbactam": "1 gm", "cefoperazone": "2 gm", "ratio": "1:2"}
    ],
    "class_wide_issues": "For class-wide issues, see Cephalosporins, Overview.",
    "adult_dose": {
      "usual_dose": "Sulbactam-Cefoperazone 2 to 4 gm/day IV or IM in equally divided doses q12h (i.e., 1 to 2 gm per day Cefoperazone activity).",
      "severe_or_refractory_infections": "Sulbactam-Cefoperazone may be increased up to 8 gm of the 1:1 ratio (i.e., 4 g Cefoperazone activity) IV in equally divided doses or 12 g (i.e., 8 gm Cefoperazone activity) of the 1:2 ratio.",
      "max_sulbactam_dose": "The recommended maximum total daily dose of Sulbactam: 4 gm."
    },
    "pediatric_dose": {
        "standard": {
            "dose": "40-80 mg/kg/day (divided q6-12h)",
            "cefoperazone_equivalent": "(20-40 mg/kg/day cefoperazone using 1:1 ratio)"
        },
        "serious_infection": {
            "dose": "160 mg/kg/day (divided q6-12h) (80 mg/kg/day cefoperazone using 1:1 ratio) OR 240 mg/kg/day (divided q6-12h) (160 mg/kg/day cefoperazone using 1:2 ratio)"
        }
    }
  },
  "renal_adjustment": {
    "notes": [
        "Dosage adjustment may be required in hepatic disease.",
        "Administer extra cefoperazone separately as needed (cefoperazone does not require dosage adjustment in renal impairment)."
    ],
    "half_life_normal": "Cefoperazone: 1.7.2.0, Sulbactam: 1.0",
    "half_life_esrd": "Cefoperazone: No change, Sulbactam: 6.9-9.7",
    "dose_renal_function_normal": "2-4 gm/day (divided q12h) (i.e., cefoperazone 1-2 gm/day)",
    "crcl_or_egfr": "Adjustment necessary for the sulbactam: CrCl â‰¥30: No dosage adjustment. CrCl 15-30: Sulbactam 1 gm q12h. CrCl <15: Sulbactam 500 mg q12h",
    "hemodialysis": "Sulbactam 500 mg q12h (AD on dialysis days)",
    "capd": "No data",
    "crrt": "Sulbactam 1 gm q8h",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "note": "Limit dosage to 2 gm/day (cefoperazone) in patients with concomitant hepatic and renal dysfunction.",
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "Limit dosage to 2 gm/day (cefoperazone)"
  },
  "adverse_effects": [
    "See Cephalosporins, Overview",
    "Hypersensitivity reactions",
    "Anaphylaxis",
    "Stevens-Johnson syndrome, toxic epidermal necrolysis",
    "C. difficile-associated diarrhea",
    "Increased LFTs",
    "Hematologic: anemia, neutropenia, thrombocytopenia",
    "May increase INR and cause bleeding, possibly related to the MTT side chain."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "susceptibility_breakpoints": "Susceptibility breakpoints established for Cefoperazone have not been re-affirmed by modern analytic criteria",
    "previous_breakpoint_activity": "At the previously established breakpoint of \"susceptible at 16 mcg/mL or less\", Sulbactam-Cefoperazone inhibited the following percentages of a large world-wide collection of organisms (Diagn Microbiol Infect Dis 88: 177, 2017):",
    "organism_activity": {
        "enterobacteriaceae": "91.4%",
        "pseudomonas_aeruginosa": "74.5%",
        "stenotrophomonas_maltophilia": "50%",
        "acinetobacter_spp": "40%"
    },
    "anaerobes": "Potent vs anaerobes"
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "Cef: 236.8 (1 gm IV over 5 min, SD), Sul: 130 (1 gm IV over 5 min, SD)",
    "peak_urine_conc_ug_ml": "Cef: >2200 (2 gm IV over 15 min, SD)",
    "protein_binding_percent": "Cef: 87-90",
    "volume_of_distribution_vd_l": "Cef: 10.2-11.3 L, Sul: 18.0-27.6 L",
    "avg_serum_half_life_hr": "Cef: 1.7-2.0, Sul: 1.0",
    "elimination": "Cef: Biliary (main), Sul: renal",
    "bile_penetration_percent": "Cef: Up to 100x serum conc",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "No data"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": "Sulbactam: OAT1, OAT3",
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
      {
          "drug": "Ethanol",
          "effect": "Possible disulfiram-type reaction",
          "management": "Avoid co-administration"
      }
  ]
}